According to Regeneron Pharmaceuticals's latest financial reports the company has $10.84 B in cash and cash equivalents.
A companyโs cash on hand also refered as cash/cash equivalents (CCE) and Short-term investments, is the amount of accessible money a business has.
Year | Cash on Hand | Change |
---|---|---|
2023-12-31 | $10.84 B | 40.07% |
2022-12-31 | $7.74 B | 35.96% |
2021-12-31 | $5.69 B | 58.76% |
2020-12-31 | $3.58 B | 11.6% |
2019-12-31 | $3.21 B | 14.39% |
2018-12-31 | $2.80 B | 99.35% |
2017-12-31 | $1.40 B | 35.7% |
2016-12-31 | $1.03 B | -0.63% |
2015-12-31 | $1.04 B | 16.07% |
2014-12-31 | $0.90 B | 29.76% |
2013-12-31 | $0.69 B | 125.25% |
2012-12-31 | $0.30 B | -41.53% |
2011-12-31 | $0.52 B | 111.31% |
2010-12-31 | $0.24 B | -26.94% |
2009-12-31 | $0.34 B | -28.1% |
2008-12-31 | $0.47 B | -38.06% |
2007-12-31 | $0.76 B | 66.88% |
2006-12-31 | $0.45 B | 53.84% |
2005-12-31 | $0.29 B | 0.87% |
2004-12-31 | $0.29 B | 0.75% |
2003-12-31 | $0.29 B | 11.16% |
2002-12-31 | $0.26 B | -31.37% |
2001-12-31 | $0.38 B |
Company | Cash on Hand | differencediff. | Country |
---|---|---|---|
Johnson & Johnson JNJ | $22.92 B | 111.41% | ๐บ๐ธ USA |
Novartis NVS | $13.96 B | 28.74% | ๐จ๐ญ Switzerland |
Amgen AMGN | $10.94 B | 0.91% | ๐บ๐ธ USA |
Sanofi SNY | $9.92 B | -8.45% | ๐ซ๐ท France |
Biogen BIIB | $1.04 B | -90.32% | ๐บ๐ธ USA |
Alnylam Pharmaceuticals
ALNY | $2.43 B | -77.51% | ๐บ๐ธ USA |